These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

229 related articles for article (PubMed ID: 15777221)

  • 1. Metal complexes with aromatic N-containing ligands as potential agents in cancer treatment.
    Zhao G; Lin H
    Curr Med Chem Anticancer Agents; 2005 Mar; 5(2):137-47. PubMed ID: 15777221
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Rhodium and its compounds as potential agents in cancer treatment.
    Katsaros N; Anagnostopoulou A
    Crit Rev Oncol Hematol; 2002 Jun; 42(3):297-308. PubMed ID: 12050021
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Current development of Pd(II) complexes as potential antitumor agents.
    Gao E; Liu C; Zhu M; Lin H; Wu Q; Liu L
    Anticancer Agents Med Chem; 2009 Mar; 9(3):356-68. PubMed ID: 19275527
    [TBL] [Abstract][Full Text] [Related]  

  • 4. DNA binding mode of ruthenium complexes and relationship to tumor cell toxicity.
    Brabec V; Nováková O
    Drug Resist Updat; 2006 Jun; 9(3):111-22. PubMed ID: 16790363
    [TBL] [Abstract][Full Text] [Related]  

  • 5. New metal complexes as potential therapeutics.
    Zhang CX; Lippard SJ
    Curr Opin Chem Biol; 2003 Aug; 7(4):481-9. PubMed ID: 12941423
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antimetastatic properties and DNA interactions of the novel class of dimeric Ru(III) compounds Na2[[trans-RuCl4(Me2SO)]2(mu-L)] (L = ditopic, non-chelating aromatic N-ligand). A preliminary investigation.
    Alessio E; Iengo E; Zorzet S; Bergamo A; Coluccia M; Boccarelli A; Sava G
    J Inorg Biochem; 2000 Apr; 79(1-4):173-7. PubMed ID: 10830863
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ruthenium complexes as anticancer agents.
    Kostova I
    Curr Med Chem; 2006; 13(9):1085-107. PubMed ID: 16611086
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Is matching ruthenium with dithiocarbamato ligands a potent chemotherapeutic weapon in oncology?
    Nardon C; Brustolin L; Fregona D
    Future Med Chem; 2016; 8(2):211-26. PubMed ID: 26807601
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Nonclassical platinum antitumor agents: perspectives for design and development of new drugs complementary to cisplatin.
    Farrell N
    Cancer Invest; 1993; 11(5):578-89. PubMed ID: 8402226
    [TBL] [Abstract][Full Text] [Related]  

  • 10. New cytotoxic and water-soluble bis(2-phenylazopyridine)ruthenium(II) complexes.
    Hotze AC; Bacac M; Velders AH; Jansen BA; Kooijman H; Spek AL; Haasnoot JG; Reedijk J
    J Med Chem; 2003 Apr; 46(9):1743-50. PubMed ID: 12699392
    [TBL] [Abstract][Full Text] [Related]  

  • 11. DNA binding by antitumor trans-[PtCl2(NH3)(thiazole)]. Protein recognition and nucleotide excision repair of monofunctional adducts.
    Kasparkova J; Novakova O; Farrell N; Brabec V
    Biochemistry; 2003 Jan; 42(3):792-800. PubMed ID: 12534292
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Multinuclear Organometallic Ruthenium-Arene Complexes for Cancer Therapy.
    Babak MV; Ang WH
    Met Ions Life Sci; 2018 Feb; 18():. PubMed ID: 29394025
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Platinum group antitumor chemistry: design and development of new anticancer drugs complementary to cisplatin.
    Abu-Surrah AS; Kettunen M
    Curr Med Chem; 2006; 13(11):1337-57. PubMed ID: 16712474
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Study of ruthenium(II) complexes with anticancer drugs as ligands. Design of metal-based phototherapeutic agents.
    Cini R; Tamasi G; Defazio S; Corsini M; Zanello P; Messori L; Marcon G; Piccioli F; Orioli P
    Inorg Chem; 2003 Dec; 42(24):8038-52. PubMed ID: 14632524
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Synthesis, characterization, and biological evaluation of new tetrazole-based platinum(II) and palladium(II) chlorido complexes--potent cisplatin analogues and their trans isomers.
    Serebryanskaya TV; Yung T; Bogdanov AA; Shchebet A; Johnsen SA; Lyakhov AS; Ivashkevich LS; Ibrahimava ZA; Garbuzenco TS; Kolesnikova TS; Melnova NI; Gaponik PN; Ivashkevich OA
    J Inorg Biochem; 2013 Mar; 120():44-53. PubMed ID: 23305964
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phenanthroline ligands are biologically more active than their corresponding ruthenium(II) arene complexes.
    Valladolid J; Hortigüela C; Busto N; Espino G; Rodríguez AM; Leal JM; Jalón FA; Manzano BR; Carbayo A; García B
    Dalton Trans; 2014 Feb; 43(6):2629-45. PubMed ID: 24327227
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Design of Ru-arene Complexes for Antitumor Drugs.
    Su W; Li Y; Li P
    Mini Rev Med Chem; 2018; 18(2):184-193. PubMed ID: 28494728
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Synthesis, structural characterization, and antitumor properties of a novel class of large-ring platinum(II) chelate complexes incorporating the cis-1,4-diaminocyclohexane ligand in a unique locked boat conformation.
    Hoeschele JD; Showalter HD; Kraker AJ; Elliott WL; Roberts BJ; Kampf JW
    J Med Chem; 1994 Aug; 37(17):2630-6. PubMed ID: 8064793
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Gold(III) complexes as potential antitumor agents: solution chemistry and cytotoxic properties of some selected gold(III) compounds.
    Messori L; Abbate F; Marcon G; Orioli P; Fontani M; Mini E; Mazzei T; Carotti S; O'Connell T; Zanello P
    J Med Chem; 2000 Sep; 43(19):3541-8. PubMed ID: 11000008
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Water-soluble Ru(II)- and Ru(III)-halide-PTA complexes (PTA=1,3,5-triaza-7-phosphaadamantane): Chemical and biological properties.
    Battistin F; Scaletti F; Balducci G; Pillozzi S; Arcangeli A; Messori L; Alessio E
    J Inorg Biochem; 2016 Jul; 160():180-8. PubMed ID: 26920229
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.